K

Kyn Therapeutics

76 employees

Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.

Basic info

Industry

biotechnology research

Sectors

translational science and biomarkers

Biotechnology

Health Diagnostics

Health Care

small molecule drug design

Targeted Oncology

cancer therapeutics development

Therapeutics

cancer biology

Date founded

2016

Funding rounds raised

Total raised

$120M

from 10 investors over 10 rounds

K

Kyn Therapeutics raised $40M on May 15, 2023

Investors: H.C. Wainwright & Co., LLC

K

Kyn Therapeutics raised $120M on January 5, 2021

Investors: HEALTHCOR LTD, Omega Funds, Farallon Capital Management, OrbiMed Advisors, Surveyor Capital, Logos Global Management, LP and The Invus Group

K

Kyn Therapeutics raised $49M on December 14, 2017

Investors: OrbiMed Advisors and Atlas Venture